US equities |
TSLA $395.86 ▲+6.35% MU $902.53 ▲+2.85% SPCX $148.17 ▲+0.46% NVDA $217.14 ▲+2.93% META $644.96 ▲+0.36% SNDK $1,257.59 ▲+1.58% AAPL $346.76 ▼-0.28% AMD $525.49 ▲+1.68%
FinancialContent

Cel-Sci Corporation Common Stock (NY:CVM)

1.590 -0.050 (-3.05%)
Delayed Quote Updated: 10:51 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
From CEL-SCI Corporation
Via Business Wire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
News headline image
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
From CEL-SCI Corporation
Via Business Wire
Why DID CVM Shares Rally Over 7% Today? ↗
Via Stocktwits
Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine ↗
Via Stocktwits
News headline image
CEL-SCI Reports Fiscal Third Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
From CEL-SCI Corporation
Via Business Wire
News headline image
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Announces Pricing of Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes $7.2 Million Public Offering
Via Investor Brand Network
News headline image
CEL-SCI Reports Fiscal Second Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Via Chartmill
News headline image
CEL-SCI Corporation Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal First Quarter 2026 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2025 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
Thursday's session: top gainers and losers ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >